论文部分内容阅读
目的观察扶正消积方治疗晚期NSCLC的临床疗效。方法选取142例晚期NSCLC患者随机分为两组:治疗组67例(扶正消积方+GP方案化疗),对照组75例(GP方案化疗),治疗4个周期后观察瘤灶变化、临床症状、Karnofsky评分、体重、不良反应及生存期。结果治疗组疾病控制率(83.58%)高于对照组(P<0.05);治疗组临床症状改善率(52.23%)明显优于对照组(P<0.01);治疗组生存质量改善优于对照组,(P<0.01);治疗组化疗期间胃肠道反应及骨髓抑制发生率低于对照组(P<0.05);治疗组1年生存率(53.73%)及中位生存期(13.33个月)均高于对照组(P<0.05)。结论扶正消积方联合化疗治疗晚期NSCLC具有一定的减毒增效作用。
Objective To observe the clinical effect of Fuzheng Xiaoji Recipe in the treatment of advanced non-small cell lung cancer. Methods A total of 142 patients with advanced NSCLC were randomly divided into two groups: 67 in the treatment group (Fuzheng Xiaoji Fang + GP chemotherapy) and 75 in the control group (GP chemotherapy). The changes of tumor focus, clinical symptoms , Karnofsky score, weight, adverse reactions, and survival. Results The disease control rate (83.58%) in the treatment group was higher than that in the control group (P <0.05). The clinical symptom improvement rate (52.23%) in the treatment group was significantly better than that in the control group (P <0.01) (P <0.01). The incidence of gastrointestinal reaction and myelosuppression in the treatment group was lower than that in the control group (P <0.05). The 1-year survival rate and the median survival time of the treatment group were 53.73% and 13.33 months, All higher than the control group (P <0.05). Conclusion Fuzheng Xiaoshi Recipe in combination with chemotherapy for the treatment of advanced NSCLC has some attenuated synergism.